Sonoma Pharmaceuticals (SNOA)

• Market cap: $7.28M
• 1 day: -0.89%
• 5 days: -1.12%
• 1 month: -17.2%
• 3 months: 43.83%
• 6 months: 14.77%
• Year to date: 65.3%
• 1 year: 5.23%
• 5 years: -96.97%
• 10 years: -99.58%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

Employees: 168

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

239% more capital invested

Capital invested by funds: $71.5K [Q1] → $242K (+$171K) [Q2]

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

18% more funds holding

Funds holding: 11 [Q1] → 13 (+2) [Q2]

3.13% more ownership

Funds ownership: 2.04% [Q1] → 5.17% (+3.13%) [Q2]